COMP <GO>
KARD vs LBRX // ALTMAN Z-SCORE & DEBT/EQUITY
Kardigan Inc. (NASDAQ) VS. LB Pharmaceuticals Inc (NASDAQ) • 15-METRIC TALLY: KARD 1
— LBRX 1
■ METRIC PARITY
LAST: $14.31 (+4.22%) • MKT CAP: $1.34B
balance-sheet
—
LAST: $40.15 (+0.80%) • MKT CAP: $1.30B
balance-sheet
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KARD VS. LBRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KARD | LBRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -8.40% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -2.72% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 2/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.1 | 52.9 | -4.82 | LBRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.34B | $1.30B | $42.8M | KARD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KARD REV | LBRX REV | KARD GROSS % | LBRX GROSS % | KARD FCF | LBRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | — | -$35.3M |
| FY 2024 | — | $0 | — | — | — | -$53.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KARD // BETA —
LBRX // BETA —